Trade groups on bird flu
This article was originally published in The Tan Sheet
Executive Summary
"Marketers and retailers of dietary supplements are urged to refuse to stock or sell any products that are presented as preventing, treating or curing avian flu," a coalition of supplement industry trade groups announces in a joint advisory issued Nov. 18. The American Herbal Products Association, Consumer Healthcare Products Association, Council for Responsible Nutrition and National Nutritional Foods Association "encourag[e] consumers to use caution should they encounter products which claim to treat or prevent the avian flu" and note that "federal law and regulations do not allow any dietary supplement product" to make such claims. Although supplements can enhance general immune function, therapies for prevention or treatment of avian flu "should only be recommended by qualified healthcare professionals or public health authorities," the groups conclude...
You may also be interested in...
“Fowl” Play? FDA Warning Letters Target Avian Flu Supplement Marketers
Nine dietary supplement firms who received FDA warning letters for marketing their products as treatments for avian flu could face "far more serious enforcement activity" if they do not take "immediate corrective action," according to an industry lawyer
‘Parity To The Originator Is Not Enough’ – Cardinal Health Talks US Biosimilars
Following what Cardinal Health described as “a year of monumental developments in biosimilars,” the firm’s director of biosimilars, Dracey Poore, spoke to Generics Bulletin for an exclusive Q&A.
Fresenius And Formycon Strike Stelara Settlement For Europe And Canada
Partners Fresenius Kabi and Formycon have laid the groundwork to launch their biosimilar ustekinumab rival to Stelara in Europe and Canada through a settlement agreement with originator J&J.